The trial is aimed to investigate the safety, pharmacokinetics and tolerability of BAL30072 following multiple ascending intravenous infusions in healthy volunteers.
BAL30072 demonstrated safety and tolerability profile in a single ascending dose Phase I trial and has also showed dose-proportional pharmacokinetic properties.
The sulfactam antibiotic BAL30072 in in vitro and in vivo models has demonstrated potent bactericidal activity against a broad range of multidrug-resistant Gram-negative pathogens such as Pseudomonas or Acinetobacter species.
Basilea CEO Anthony Man said the company expects to complete the second study in the first half of 2012.